- |||||||||| Alymsys (bevacizumab-maly) - Amneal, Pharmaceutical Libbs, Grupo Insud, Nichi / Iko, Stada
Trial completion, Enrollment change, Trial primary completion date: Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN (clinicaltrials.gov) - May 21, 2016 P1, N=142, Completed, Recruiting --> Active, not recruiting Recruiting --> Completed | N=100 --> 142 | Trial primary completion date: Apr 2016 --> Oct 2015
- |||||||||| BI 695502 (bevacizumab biosimilar) / Boehringer Ingelheim
New P3 trial, Metastases: INVICTAN (clinicaltrials.gov) - May 18, 2016 P3, N=120, Not yet recruiting,
- |||||||||| Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment closed, Trial primary completion date, Metastases: FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer (clinicaltrials.gov) - May 10, 2016 P2, N=64, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Sep 2016
- |||||||||| conatumumab (AMG 655) / Amgen
Trial primary completion date: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - May 9, 2016 P2, N=12, Active, not recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Sep 2016 Trial primary completion date: Jul 2016 --> Jan 2017
- |||||||||| Cyramza (ramucirumab) / Eli Lilly
Enrollment closed, Trial primary completion date, Metastases: A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer (clinicaltrials.gov) - May 6, 2016 P1, N=9, Active, not recruiting, Trial primary completion date: Jul 2016 --> Jan 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Oct 2016
- |||||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Enrollment change, Combination therapy, Metastases: Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors (clinicaltrials.gov) - May 6, 2016 P1, N=60, Recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Oct 2016 Not yet recruiting --> Recruiting | N=80 --> 60
- |||||||||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion, Trial initiation date, Trial primary completion date, Metastases: The Study of Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - May 4, 2016 P1/2, N=73, Completed, Active, not recruiting --> Completed Enrolling by invitation --> Completed | Initiation date: Aug 2011 --> Mar 2012 | Trial primary completion date: Feb 2012 --> Apr 2016
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Metastases: FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma (clinicaltrials.gov) - Apr 22, 2016 P2, N=35, Recruiting, Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Sep 2017
- |||||||||| telisotuzumab (h224G11) / AbbVie
Trial primary completion date, Metastases: Study of ABT-700 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Apr 22, 2016 P1, N=124, Active, not recruiting, Trial primary completion date: Dec 2015 --> Sep 2017 Trial primary completion date: Apr 2016 --> Oct 2016
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Trial primary completion date, Metastases: Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Apr 21, 2016 P1, N=70, Active, not recruiting, Trial primary completion date: Dec 2015 --> Sep 2016 Trial primary completion date: Jun 2015 --> Jun 2016
|